JPMorgan Chase & Co. Decreases Holdings in Lantheus Holdings Inc (LNTH)

JPMorgan Chase & Co. lowered its position in Lantheus Holdings Inc (NASDAQ:LNTH) by 24.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 982,206 shares of the medical equipment provider’s stock after selling 325,025 shares during the period. JPMorgan Chase & Co.’s holdings in Lantheus were worth $14,685,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. LSV Asset Management raised its holdings in Lantheus by 135.6% in the 3rd quarter. LSV Asset Management now owns 865,921 shares of the medical equipment provider’s stock valued at $12,945,000 after buying an additional 498,435 shares during the period. Virginia Retirement Systems ET AL grew its position in Lantheus by 8.3% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 55,000 shares of the medical equipment provider’s stock valued at $822,000 after acquiring an additional 4,200 shares in the last quarter. Cadence Capital Management LLC grew its position in Lantheus by 402.4% in the 3rd quarter. Cadence Capital Management LLC now owns 142,150 shares of the medical equipment provider’s stock valued at $2,125,000 after acquiring an additional 113,854 shares in the last quarter. Gabelli Funds LLC grew its position in Lantheus by 216.1% in the 3rd quarter. Gabelli Funds LLC now owns 190,000 shares of the medical equipment provider’s stock valued at $2,841,000 after acquiring an additional 129,900 shares in the last quarter. Finally, Gamco Investors INC. ET AL grew its position in Lantheus by 227.5% in the 3rd quarter. Gamco Investors INC. ET AL now owns 49,951 shares of the medical equipment provider’s stock valued at $747,000 after acquiring an additional 34,700 shares in the last quarter. Institutional investors own 92.39% of the company’s stock.

In other Lantheus news, insider Cesare Orlandi sold 7,055 shares of Lantheus stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $18.01, for a total value of $127,060.55. Following the completion of the transaction, the insider now directly owns 86,064 shares of the company’s stock, valued at approximately $1,550,012.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Several research firms have weighed in on LNTH. ValuEngine raised Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, December 1st. BidaskClub raised Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, November 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $22.67.

NASDAQ LNTH opened at $17.38 on Friday. The stock has a market capitalization of $700.45 million, a price-to-earnings ratio of 21.68, a PEG ratio of 4.23 and a beta of 1.44. The company has a debt-to-equity ratio of 4.76, a current ratio of 3.50 and a quick ratio of 2.87. Lantheus Holdings Inc has a 1-year low of $12.59 and a 1-year high of $24.45.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, October 30th. The medical equipment provider reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.06. The company had revenue of $88.90 million during the quarter, compared to the consensus estimate of $83.53 million. Lantheus had a return on equity of 83.95% and a net margin of 36.75%. Lantheus’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. On average, sell-side analysts forecast that Lantheus Holdings Inc will post 0.86 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Decreases Holdings in Lantheus Holdings Inc (LNTH)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/12/07/jpmorgan-chase-co-decreases-holdings-in-lantheus-holdings-inc-lnth.html.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Featured Article: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply